Complexa, Inc.
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
33.3%
3 terminated/withdrawn out of 9 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Oral CXA-10 in Pulmonary Arterial Hypertension
Role: collaborator
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
Role: lead
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
Role: lead
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
Role: lead
Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
Role: lead
Study of CXA-10 in Healthy Volunteers
Role: lead
Oral CXA-10 Study in Healthy Volunteers
Role: lead
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
Role: lead
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
Role: lead
All 9 trials loaded